Manufacturing: Page 20


  • Mylan taken to task for manufacturing failings at key plant

    A warning letter issued by the FDA is the first received by the drugmaker for its Morgantown, West Virginia facility since the site was established in 1966.

    By Ned Pagliarulo • Nov. 21, 2018
  • Cambrex acquires Avista in $250M deal

    Analysts note the deal, which gives Cambrex facilities as well as new capabilities, will make the company more competitive in the CDMO space.

    By Suzanne Elvidge • Nov. 21, 2018
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Catalent bringing 2nd clinical supply facility to China

    The contract manufacturer expects to invest $2.5 million in the facility and officially open it in early 2019.

    By Suzanne Elvidge • Nov. 15, 2018
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    3D printing poised to disrupt healthcare

    Health industry types are "100% convinced, and rightly so, that [3D printing] will be a core part of their business in five to 10 years," ISG's Michael Harmon said.

    By Meg Bryant • Nov. 12, 2018
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    AmerisourceBergen's compounding site still on ice despite beefed-up oversight

    Form 483s issued by the FDA have raised questions about PharMEDium's procedures to ensure quality control.

    By Nov. 8, 2018
  • Image attribution tooltip
    Lonza Ltd.
    Image attribution tooltip

    Lonza ups stake in Octane, furthering cell therapy bet

    Octane's technology, which Lonza has collaborated on since 2015, is designed to manufacture cell therapies through a closed, automated system.

    By Suzanne Elvidge • Nov. 1, 2018
  • Allergan axes expansion plan, but reiterates commitment to Waco plant

    With generic competition for Restasis looming, Allergan is stepping back from previous plans to expand its Texas manufacturing facility.

    By Suzanne Elvidge • Nov. 1, 2018
  • Supply shortages weigh on Pfizer's sterile injectables business in Q3

    The pharma doesn't expect to see improvement until late 2019, leaving several quarters yet of ongoing manufacturing challenges.

    By Suzanne Elvidge • Nov. 1, 2018
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Astellas invests $257M in trans-Pacific manufacturing build-out

    A major focus of the planned construction will be on building capacity for cell therapy and regenerative medicine development.

    By Suzanne Elvidge • Nov. 1, 2018
  • Image attribution tooltip
    Yujin Kim/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Red pill or blue? It could be a billion-dollar decision

    Viagra and Nexium ​underscore how marketers and manufacturers can use color to make a drug franchise more successful.

    By Oct. 29, 2018
  • Endocyte deal showcases Novartis' complex manufacturing juggling act

    Radioligands, CAR-T medicines, gene therapies: Novartis is working on all of them, creating some pretty substantial production challenges.

    By Oct. 25, 2018
  • GSK opens new Ellipta plant in Scotland

    Growing demand means greater investment needed in manufacturing for the franchise, set against a background of job cuts across the company.

    By Suzanne Elvidge • Oct. 25, 2018
  • Merck KGaA expands manufacturing site at German HQ

    The new production facility is 15,000-square-meters and is located in the German pharma giant's historic headquarters in Darmstadt.

    By Suzanne Elvidge • Oct. 24, 2018
  • Image attribution tooltip
    Novartis AG
    Image attribution tooltip

    Cryoport, in pursuit of smoother cell therapy logistics, opens new facility

    Located in Livingston, New Jersey, the center is in close proximity to major cell therapy players like Novartis and Celgene.

    By Oct. 24, 2018
  • Lonza plans to lay off 60 workers at Maryland plant beginning in December

    As Lonza refocuses its manufacturing on four cell and gene therapy centers, a plant in Walkersville, Maryland, will see more than 100 workers affected and dozens expected to be laid off.

    By Suzanne Elvidge • Oct. 23, 2018
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck to create 170 jobs with new Ireland expansion

    The big pharma has invested in its manufacturing network as demand climbs for vaccines and biologics.

    By Suzanne Elvidge • Oct. 18, 2018
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    Acacia Pharma pitches quick path to refiling Barhemsys

    A Complete Response Letter from the FDA earlier this month derailed Acacia's plans for its lead drug, but it hopes to soon get back on track.

    By Suzanne Elvidge • Oct. 18, 2018
  • Managing inventory: What retail can learn from pharma

    Retail and pharma are vastly different industries. But the tightly controlled world of drug supply still holds lessons for consumer goods. 

    By Gary Wollenhaupt • Oct. 18, 2018
  • Image attribution tooltip
    Shire media relations
    Image attribution tooltip

    Shire debuts plasma facility in boost to manufacturing

    Earlier this year, the biotech secured FDA approval for Gammaguard Liquid produced at the site.

    By Suzanne Elvidge • Oct. 18, 2018
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Expansion gives Almac room to grow in North Carolina

    The CDMO opened a fourth building at its Durham campus, with space to add more than 100 employees over the next three years.

    By Ned Pagliarulo • Oct. 11, 2018
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Regulators wary of how McKesson handles illegitimate drugs

    A Form 483 issued in July found the drug distributor didn't have proper systems for addressing illegitimate products when they came through its facilities.

    By Oct. 11, 2018
  • Image attribution tooltip
    Lonza Ltd.
    Image attribution tooltip

    Lonza boosts ADC manufacturing with new investment

    Antibody-drug conjugates have occupied a corner of the biologic market for years. Lonza, though, is betting on faster growth.

    By Suzanne Elvidge • Oct. 10, 2018
  • Manufacturers cite a 'workforce crisis' as the top threat to business

    One in four manufacturers have turned down new business due to problems getting "quality" labor, a National Association of Manufacturers survey found.

    By Edwin Lopez • Oct. 9, 2018
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sarepta builds out gene therapy manufacturing with latest CDMO deal

    The biotech is thinking ahead, inking partnerships in recent months with Paragon Bioservices and Brammer Bio to support its gene therapy pipeline.​

    By Suzanne Elvidge • Oct. 9, 2018
  • Dr Reddy's sells off Tennessee antibiotics facility in restructuring push

    By 2021, the Indian drugmaker hopes to shift the majority of its North American business from solid oral dosages to injectables.

    By Suzanne Elvidge • Oct. 4, 2018